- Partners Personalized Medicine Lab for Molecular Medicine
Partners HealthCare Personalized Medicine - Laboratory for Molecular Medicine
The Laboratory for Molecular Medicine (LMM) is a CLIA-certified molecular diagnostic laboratory, operated by Partners HealthCare Personalized Medicine. The LMM is led by a group of Harvard Medical School-affiliated faculty, geneticists, clinicians, and researchers from Brigham and Women’s Hospital and Massachusetts General Hospital, Partners' founding members. Our mission is to bridge the gap between research and clinical medicine by remaining focused on the following:
-Leading the implementation of advanced technologies and practices into molecular diagnostic testing;
-Accelerating the adoption of new molecular tests into clinical care;
-Incorporating information technology (IT) support into the day-to-day operations of the clinical laboratory; and
-Advancing clinical care with our participation in innovative programs, aiming to keep physicians current on and knowledgeable of genetic information relevant to their patients.
Through this work, the LMM is taking the promise of personalized medicine from the lab and into the clinic. Each year, we provide services to more than 4,000 patients and their physicians through over 100 targeted genetic tests, whole gene sequencing, and now, whole exome sequencing. From detecting presymptomatic heart conditions such as cardiomyopathy (Pan Cardiomyopathy Panel), to tests for genetic-based hearing loss in children (OtoGenomeTM), and diagnosing lung conditions (PulmoGene Panel), we are working with researchers and physicians to make a difference in the lives of patients.
We offer comprehensive testing services to support clinical research and clinical practice. Working with LMM, you and your team will have access to:
-A wide range of tests, including single gene, multiple gene panel, genome sequencing, and now exome sequencing. All next-generation sequencing panels have now been updated to include Copy Number Variant (CNV) Analysis at no additional charge.
- Tests are offered in the following areas:
- Pan Cardiomyopathy Panel (62 genes)
- Hypertrophic Cardiomyopathy (HCM) Panel (20 Genes)
- Dilated Cardiomyopathy (DCM)/Arrhythmogenic Cardiomyopathy Panel (53 Genes)
- Congenital Heart Defects
- Connective Tissue
- Connective Tissue Disorders Panel (14 genes)
- Ectodermal Dysplasia
- Exome Sequencing
- ExomePLUS Sequencing
- Genome Sequencing
- Hearing Loss
- OtoGenome Test™ for hearing loss and related syndrome (87 genes)
- Usher Syndrome Panel (11 genes)
- Pulmonary Disease
- PulmoGene Panel for inherited pulmonary disorders (64 genes)
- Expanded RASopathy Panel Noonan syndrome and related RASopathies (14 genes)
- Renal Disease
-Prominent clinical molecular geneticists, researchers, physicians and genetic counselors within the Harvard Medical School and the Partners HealthCare system;
-GeneInsight Suite®, an advanced system that streamlines the interpretation and management of genetic data and knowledge. The system is capable of generating real time alerts to clinicians when the LMM changes classification of variants previously identified in one or more of their patients; and
-Comprehensive, accurate, evidence-based, personalized reports that are clinically meaningful.
For a test menu, please click here: LMM Test Menu
For prices and CPT codes, please click here: LMM Prices and CPT Codes
Benefits to Working With Us
We're here to help
We’ll assist you through every step of the process of genetic testing from ordering through reporting and result interpretation. The LMM’s test menu offers an array of clinically relevant and studied gene panels developed on the most advanced technology platforms. Our team of experts will help you determine the best testing strategy for your clinical case, guiding you in choosing the most appropriate panel testing for your needs. Results are thoroughly reviewed and translated in a streamlined manner specific to your patient’s phenotype and genotype and are explained to you and, if need be, to your patient.
At the Laboratory for Molecular Medicine (LMM), we tackle the toughest challenges associated with the advancement and adoption of personalized medicine. As innovative leaders, we build solutions from the ground up.
LMM incorporates scientific discoveries and breakthrough technologies into our clinical laboratory to provide the most comprehensive genetic information. The LMM offers many benefits, including:
We offer multiple panels in disease areas, as well as genome and exome sequencing to help end the diagnostic odyssey. By offering panels that test across clinical presentation we can improve the chance that clinicians and patients will find the disease causing gene variants.
Our GeneInsight® information technology (IT) platform – one of the most advanced systems in the industry – streamlines the management, sharing, and interpretation of vast amounts of genetic data.
The system facilitates the process of generating concise, patient specific and consistent reports and helps the laboratory continuously improve its variant classification.
We provide comprehensive, accurate, evidence-based reports that are developed by a team of experts and are clinically meaningful. We believe that high-quality clinical reports are essential for the integration of genetic knowledge into clinical practice. And, our specialists are available to assist with interpretation of results.
Real-time clinical updates
As our knowledge base on genetic variants grows over time, we share this new information with you through GeneInsight Clinic®. We update clinicians as new information emerges on variants identified in patient profiles.
A team of experts
Our reputation for scientific leadership and quality is a direct result of our people. All of our Lab Directors hold faculty appointments at Harvard Medical School and actively pursue clinical research.
Our network infrastructure facilitates interconnectivity among genetic testing laboratories and clinicians. This functionality also supports the formation of inter-laboratory collaborations and knowledge sharing, and that enable laboratories to share knowledge, essential to new discoveries to improve patient care.
The Laboratory for Molecular Medicine (LMM) is a CLIA-certified clinical diagnostic laboratory through Massachusetts General Hospital, a Harvard Medical School Teaching Hospital, operating within the Partners HealthCare Personalized Medicine. The LMM offers more than 100 genetic tests, covering a wide range of complex and single gene disorders, as well as whole genome sequencing.
We are focused on providing the most comprehensive service for our clients by offering a large portfolio of tests. We also include Copy Number Variation (CNV) service as part of all targeted next-generation sequencing (NGS) gene panels at no additional cost.
How to Order
As collaborators, we offer great depth of clinical knowledge to guide you through test selection and interpretation. The ordering process is as follows:
-Complete a requisition and consent form for the test being ordered (see requisition forms under disease-specific pages).
-Collect a blood or saliva sample to run the test (see sample requirements).
-Make payment for the test (see methods of payment).
-Send the completed forms and sample to the LMM (see shipping).
-Once testing is completed, the health care provider receives a report and discusses the test results with our licensed genetic counselors.
Please note that only health care providers (i.e., geneticist, cardiologist, genetic counselor) can order a genetic test. A patient cannot order a genetic test for him/herself.
For further ordering information, please click here: Ordering Information
For further information regarding Sample Requirements, Payments, and Shipping, please visit: Information on Sample Requirements, Payments, and Shipping